Dexak 25 mg 30 tablets

Dexak 25 mg 30 tablets

OTC medication

NAME OF MEDICINAL PRODUCT: Dexak, 25 mg film-coated tablets.

QUALITATIVE AND QUANTITATIVE COMPOSITION: each tablet contains 25 mg of decsketoprofen (Dexketoprofenum) in the form of decsketoprofen with tromethamol.

PHARMACEUTICAL FORM: Dexak: white, round, convex on both sides coated tablets with a dividing line. Tablets can be divided into equal doses.

INDICATIONSFOR USE Dexak 25 mg.

Symptomatic treatment of pain of mild to moderate intensity, e.g. pain in the muscular and osteoarticular system, painful menstruation, toothache

INDICATIONS Dexak 25 mg

Dexak tablets must not be used in the following cases: in patients with hypersensitivity to the active substance, other drugs from the group of non-steroidal anti-inflammatory drugs (NSAIDs) or to any of the excipients; in patients in whom substances with a similar mechanism of action (such as. acetylsalicylic acid or other NSAIDs) trigger an asthma attack, bronchospasm, acute rhinitis, or cause nasal polyps, urticaria, or angioedema; in patients with a history of photoallergic or phototoxic reactions while using ketoprofen or fibrates; In patients with a history of gastrointestinal bleeding or perforation associated with prior NSAID treatment; In patients with active gastric ulcer disease or bleeding or suspected bleeding, as well as a history of gastrointestinal bleeding, ulceration or perforation; In patients with chronic indigestion; in patients with other active bleeding or bleeding disorders; in patients with Crohn's disease or ulcerative colitis; in patients with severe heart failure; in patients with moderate or severe renal insufficiency (creatinine clearance ≤59 ml/min); in patients with severe hepatic impairment (10-15 points on the Child's-Pugh scale); in patients with hemorrhagic diathesis and other blood clotting disorders; in patients who are severely dehydrated (due to vomiting, diarrhea or insufficient fluid intake); in women in the third trimester of pregnancy and during lactation.

RESPONSIBLE COMPANY WITH THE AUTHORIZATION TO MARKET Berlin-Chemie AG (Menarini Group)Glienicker Weg 125, 12489 Berlin, Germany, updated 03.2023.

SCIENTIFICINFORMATION: BERLIN-CHEMIE/MENARINI POLSKA Sp. z o.o. 4 Słomińskiego St., 00-204 Warsaw, tel. 22 566 21 00

Before use, read the leaflet, which contains indications, contraindications, data on adverse reactions and dosage, and information on the use of the medicinal product, or consult your doctor or pharmacist, as any drug used inappropriately threatens your life or health.